Professional Background:

Douglas is the Head of Research and Development at GlyTherix and leads the scientific team. He has 20 years of experience in biomedical research with a particular focus on drug development and oncology. He led the development of the Miltuximab anti-GPC-1 monoclonal antibody from preclinical studies to First in human clinical trials, and has previously been involved in the development of a novel antibody for the treatment of multiple myeloma (MDX-1097) from pre-clinical to Phase 2 clinical trials. Douglas has been supported by ARC, NHMRC Development Grants together with Commercial Ready, Commercialisation Australia and CRC-P grants.

Research Interests:

GlyTherix is focussed on the theranostic Miltuximab monoclonal antibody for the treatment of solid cancers. The team has expertise in monoclonal antibody development, preclinical studies to support first in human clinical trials and the development of radiolabelled antibodies for cancer. The laboratory is based at Macquarie University in Sydney.